Solid Tumor, Adult
Conditions
Keywords
anti-PD-1 / PD-L1 antibodies approved, HER2+, Metastatic CRC, Head and Neck Squamous Cell Carcinoma, NK Cells, Urothelial Cancer, Renal Cell Carcinoma, merkel cell carcinoma, non-small cell lung cancer, NSCLC, triple negative breast cancer, immune checkpoint inhibitor, melanoma, renal cell carcinoma, lung cancer,, triple-negative breast cancer,, head and neck squamous cell carcinoma,, urothelial carcinoma (UC),, Merkel cell carcinoma, squamous, hepatocellular carcinoma, gastric cancer, esophageal cancer, endometrial cancer,
Brief summary
This is a Phase 1 dose-finding study of FT538 in combination with monoclonal antibodies.
Detailed description
This is a Phase 1 dose-finding study of FT538 given in combination with a monoclonal antibody following lymphodepletion in subjects with advanced solid tumors. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.
Interventions
DRUGFT538
FT538 is an allogeneic natural killer (NK)-cell immunotherapy
DRUGCyclophosphamide
Lympho-conditioning agent
DRUGFludarabine
Lympho-conditioning agent
COMBINATION_PRODUCTMonoclonal antibody - Dose Escalation
either avelumab, trastuzumab or cetuximab
COMBINATION_PRODUCTMonoclonal antibody - Dose Expansion
either avelumab, atezolizumab, nivolumab, pembrolizumab, trastuzumab or cetuximab
Sponsors
Fate Therapeutics
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Subjects with locally advanced or metastatic disease who have progressed after at least one line of therapy and diagnosis of one of the following by treatment cohort: * Cohort A: The following solid tumor malignancies where anti-PD-1/PD-L1 antibodies are approved: cutaneous melanoma, non-small cell/small cell lung cancer, renal cell carcinoma, head and neck squamous cell cancer, microsatellite instability-high/ mismatch repair deficient cancer, gastric cancer, esophageal cancer, cervical cancer, merkel cell carcinoma, endometrial carcinoma, tumor mutation burden-high ≥ 10 mutations/megabase\], cutaneous squamous cell carcinoma, triple-negative breast cancer. * Cohort B: HER2+ breast cancer that has relapsed or progressed on trastuzumab and progressed on either pertuzumab or HER2-targeting antibody drug conjugate; HER2+ gastric cancer that has relapsed or progressed on trastuzumab-containing therapy; OR any other HER2+ solid tumor having progressed on at least one line of standard-of-care therapy. For any tumor type in this cohort, HER2 status must be documented by a U.S. Food and Administration (FDA) approved test to be ≥2+ IHC or Average HER2 copy number ≥4 signals per cell by in situ hybridization. * Cohort C: CRC having progressed following prior cetuximab treatment or has KRAS/NRAS mutation; HNSCC having progressed following prior cetuximab. Capable of giving signed informed consent Aged \ 18 years old Willingness to comply with study procedures and duration Measurable disease per RECIST v1.1 For subjects with \>1 measurable lesion by RECIST v1.1 that can be safely accessed, willingness to undergo tumor biopsy Contraceptive use for women and men as defined in the protocol
Exclusion criteria
Pregnant or breast-feeding women ECOG performance status greater than or equal to 2 Evidence of insufficient organ function Clinically significant cardiovascular disease including left-ventricular ejection fraction \< 45% Receipt of therapy within 2 weeks prior to Day 1 or five half-lives, whichever is shorter or any investigational therapy within 28 days prior to Day 1 Known active central nervous system (CNS) involvement by malignancy that hasn'thas not remained stable for at least 3 months following effective treatment for CNS disease Non-malignant CNS disease such as stroke, epilepsy, CNS vasculitis or neurodegenerative disease or receipt of medications for these conditions Currently receiving or likely to require immunosuppressive therapy Active bacterial, fungal, or viral infections including hep B, Hep C or HIV Live vaccine within 6 weeks prior to start of lympho-conditioning Known allergy to albumin (human) or DMSO
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Define the Recommended Phase 2 Dose (RP2D) | Up to ~1.5 years | To define the RP2D of FT538 in combination with the following mAbs in subjects with advanced solid tumors: avelumab, trastuzumab, cetuximab, atezolizumab, nivolumab, and pembrolizumab |
| Incidence and Severity of Adverse Events (AEs)0 | Up to ~5 years | To evaluate the safety and tolerability of FT538 in combination with the following mAbs in subjects with advanced solid tumors: avelumab, trastuzumab, cetuximab, atezolizumab, nivolumab, and pembrolizumab |
Countries
United States
Outcome results
None listed